References

• Bousset L, Gil J. Targeting senescence as an anticancer therapy. Mol Oncol. 2022;16(21):3855-3880. google scholar
• McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2018;217(1):65-77. google scholar
• Boz Er AB. Integrin beta3 reprogramming stemness in HER2-positive breast cancer cell lines. Biology (Basel). 2024;13(6). doi:10.3390/biology13060429 google scholar
• Boz Er AB, Er I. Targeting ITG3 to overcome trastuzumab re-sistance through epithelial-mesenchymal transition regulation in HER2-positive breast cancer. Int J Mol Sci. 2024;25(16):8640. doi: 10.3390/ijms25168640 google scholar
• Pan X, Yi M, Liu C, et al. Cilengitide, an alphavbeta3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered. 2022;13(2):4557-4572. google scholar
• Pang X, He X, Qiu Z, et al. Targeting integrin pathways: Mech-anisms and advances in therapy. Signal Transduct Target Ther. 2023;8(1):1. doi:10.1038/s41392-022-01259-6 google scholar
• Kitsugi K, Noritake H, Matsumoto M, et al. Inhibition of inte-grin binding to ligand arg-gly-asp motif induces AKT-mediated cellular senescence in hepatic stellate cells. Mol Cell Biochem. 2023;479(10):2697-2710. google scholar
• Fujita M, Sasada M, Eguchi M, et al. Induction of cellular senes-cence in fibroblasts through beta1-integrin activation by tenascin-C-derived peptide and its protumor effect. Am J Cancer Res. 2021;11(9):4364-4379. google scholar
• Rapisarda V, Borghesan M, Miguela V, et al. Integrin beta 3 regulates cellular senescence by activating the TGF-beta pathway. Cell Rep. 2017;18(10):2480-2493. google scholar
• Franovic A, Elliott KC, Seguin L, Camargo MF, Weis SM, Cheresh DA. Glioblastomas require integrin alphavbeta3/PAK4 signaling to escape senescence. Cancer Res. 2015;75(21):4466-4473. google scholar
• Wang B, Han J, Elisseeff JH, Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024. doi:10.1038/s41580-024-00727-x google scholar
• Borah A, Kumar DS. Chapter 8 - Targeting the Hedgehog and Notch Signaling Pathways in Cancer Stem Cells. In: Dammacco F, Silvestris F, eds. Oncogenomics. Academic Press; 2019:103-120. google scholar
• Yoshida Y, Hayashi Y, Suda M, et al. Notch signal-ing regulates the lifespan of vascular endothelial cells via a p16-dependent pathway. PLoS One. 2014;9(6):e100359. doi:10.1371/journal.pone.0100359 google scholar
• Lainez-Gonzalez D, Serrano-Lopez J, Alonso-Dominguez JM. Understanding the Notch signaling pathway in acute myeloid leukemia stem cells: From Hematopoiesis to Neoplasia. Cancers (Basel). 2022;14(6). doi:10.3390/cancers14061459 google scholar
• Zou Y, Wu S, Hu Q, et al. Sonic hedgehog restrains the ubiquitin-dependent degradation of SP1 to inhibit neuronal/glial senes-cence associated phenotypes in chemotherapy-induced periph-eral neuropathy via the TRIM25-CXCL13 axis. J Adv Res. 2024. doi:10.1016/j.jare.2024.03.006 google scholar
• Cho A, Park SR, Kim SR, et al. An endogenous anti-aging factor, sonic hedgehog, suppresses endometrial stem cell aging through SERPINB2. Mol Ther. 2019;27(7):1286-1298. google scholar
• Kumari R, Jat P. Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol. 2021;9:645593. doi:10.3389/fcell.2021.645593 google scholar
• Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: Advances and future directions. Nat Rev Drug Discov. 2023;22(2):101-126. google scholar
• Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445-464. doi:10.1038/nrclinonc.2015.61 google scholar
• Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: Im-plications for HER2-targeted therapeutics. Drug Discov Today. 2011;16(17-18):810-816. doi:10.1016/j.drudis.2011.06.003 google scholar
• Prasad D, Baldelli E, Blais EM, et al. Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br J Cancer. 2024;131:1543-1554 google scholar
• Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109. doi:10.1186/s12964-023-01302-1 google scholar
• Maass KF, Kulkarni C, Betts AM, Wittrup KD. Determina-tion of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design. AAPS J. 2016;18(3):635-646. google scholar
• Ali K, Nabeel M, Mohsin F, et al. Recent developments in tar-geting breast cancer stem cells (BCSCs): A descriptive review of therapeutic strategies and emerging therapies. Med Oncol. 2024;41(5):112. doi:10.1007/s12032-024-02347-z google scholar
• Duro-Sanchez S, Nadal-Serrano M, Lalinde-Gutierrez M, et al. Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer. Cancer Res. 2022;82(24):4670-4679. google scholar
• Billimoria R, Bhatt P. Senescence in cancer: Advances in detection and treatment modalities. Biochem Pharmacol. 2023;215:115739. doi:10.1016/j.bcp.2023.115739 google scholar
• Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to thera- peutic opportunities. Nat Rev Mol Cell Biol. 2021;22(2):75-95. doi:10.1038/s41580-020-00314-w google scholar
• Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017;17(3):145-159. google scholar
• Andersson ER, Sandberg R, Lendahl U. Notch signaling: Simplicity in design, versatility in function. Development. 2011;138(17):3593-3612. google scholar

Citations